Received Jul 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | N4935 | — |
Severe case of CIDP; This serious case was reported by a consumer and described the occurrence of chronic inflammatory demyelinating polyneuropathy in a 48-year-old female patient who received DTPa (Reduced antigen) (Boostrix) solution for injection (batch number N4935 with expiry date 19-MAY-2028) for prophylaxis. On 04-APR-2026, the patient received Boostrix .5 ml. On 22-APR-2026, 18 days after receiving Boostrix, the patient experienced chronic inflammatory demyelinating polyneuropathy (Verbatim: Severe case of CIDP) (serious criteria hospitalization and GSK medically significant). The outcome of the chronic inflammatory demyelinating polyneuropathy was not resolved. It was unknown if the reporter considered the chronic inflammatory demyelinating polyneuropathy to be related to Boostrix. The company considered the chronic inflammatory demyelinating polyneuropathy to be unrelated to Boostrix. Additional Information: GSK Receipt Date: 06-JUL-2026 The patient had a severe case of CIDP with nerve damage and nerve loss, which made unassisted mobility impossible.; Sender's Comments: Chronic inflammatory demyelinating polyradiculoneuropathy, 18 days after vaccination with Boostrix in a 48-year-old female patient. Case lacks further information on medical history, concurrent conditions and concomitant medication. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Further follow up information has been sought.